Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02207075 · ClinicalTrials.gov registry record
Measuring Active Microglia in Progressive Multiple Sclerosis
A clinical trial, sponsored by Weill Medical College of Cornell University.
- Completed
- Registry status
- 50
- Enrollment target
NCT02207075: Completed study, sponsored by Weill Medical College of Cornell University.
NCT02207075 is a clinical trial that has completed, run by Weill Medical College of Cornell University. The registered enrollment target is 50 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02207075 has completed, sponsored by Weill Medical College of Cornell University.
- COMPLETED
- Registry status
- 50 participants
- Enrollment target
Study Summary
This is pilot study designed to quantifying the innate immune inflammatory burden in a cohort of secondary progressive multiple sclerosis subjects. Innate immunity is recognized as a major cause of tissue injury in central nervous system (CNS) disease. Our hypothesis is that the innate immune response is heightened in SPMS as compared to healthy controls (HC's) and this activity increases over time and correlates with ongoing neuronal loss and disability. The investigators will test this hypothesis by using highly specific molecular imaging techniques, specifically PET, in conjunction with high field MRI. The investigators will utilize the PET radioligand \[11C\]PK11195 which will be used as a marker of activated macrophages/microglia. The investigators will correlate \[11C\]PK11195 uptake with conventional measures of inflammation and neuronal integrity on high-resolution MRI. SPMS subjects will have two baseline \[11C\]PK-11195 PET scans (separated by 24 to 72 hours, test-retest) and subsequent scans at 6, 12 and 24 months. SPMS Subjects will have brain MRI's at baseline, 6, 12 and 24 months. Healthy Controls will have 2 baseline PET scans and one MRI.
Interventions
- DRUG [C11]PK-1195 PET scan
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 50 participants |
| Start Date | 2014-07 |
| Est. Completion | 2020-12 |
What the finished NCT02207075 record still lists
NCT02207075 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 50 participants, a relatively small participant target.
The record links to 0 conditions, and to 1 intervention - of which [C11]PK-1195 PET scan is the first listed.
NCT02207075 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT02207075 about?
NCT02207075 is a clinical study titled "Measuring Active Microglia in Progressive Multiple Sclerosis". This is pilot study designed to quantifying the innate immune inflammatory burden in a cohort of secondary progressive multiple sclerosis subjects. Innate immunity is recognized as a major cause of tissue injury in central nervous system (CNS) disease. Our hypothesis is that the innate immune respon...
What is the current status of trial NCT02207075?
This trial is currently completed. The enrollment target is 50 participants. The study started on 2014-07. Estimated completion is 2020-12.
What interventions are being tested in trial NCT02207075?
The interventions under investigation include: [C11]PK-1195 PET scan (DRUG).
Who is sponsoring clinical trial NCT02207075?
This trial is sponsored by Weill Medical College of Cornell University, which has 701 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00200889 · 50 participants · Early Phase 1
Mapping Auricular Vagus Nerve Circuitry
- NCT00409435 · 50 participants · Phase 2
A Study of Pyridostigmine in Postural Tachycardia Syndrome
- NCT01202305 · 50 participants
The Use of Lymph Node Biopsies to Support HIV Pathogenesis Studies
- NCT01225913 · 50 participants · Phase 4
Mechanism(s) of Airflow Limitation During Exacerbation of Asthma
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia